From ancient remedy to modern use: cannabis and cannabinoids in cancer care in the United States
Abstract
Cannabis, an ancient plant that has been used for millennia, is increasingly utilized by patients with cancer to alleviate symptoms related to both the disease and its treatment. This complex botanical contains multiple bioactive compounds, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the endogenous endocannabinoid system. THC has been studied the most, and synthetic cannabinoids are approved for the management of chemotherapy-induced nausea and vomiting. However, evidence supporting cannabis for other cancer-related symptoms—including chemotherapy-induced peripheral neuropathy, insomnia, appetite stimulation, and non-neuropathic pain—remains limited. CBD alone has not demonstrated consistent or meaningful clinical benefit. Although preclinical data exist, there is no clinical evidence supporting cannabis as a cancer treatment. Cannabis may interact with prescribed medications, particularly with high-dose oral formulations, and its effects on immunotherapy are under investigation. Overall, cannabis is generally well tolerated, though adverse effects can be significant. Use is discouraged in individuals under 25 years of age due to ongoing neurodevelopment, and patients with active psychiatric or cardiovascular conditions should use cannabis only under close clinical supervision.
Related
- Effectiveness and safety of different administration routes of medical cannabis or cannabinoids for chronic pain in adults: a systematic review and network meta-analysis with GRADE assessment
- Post-Traumatic Epilepsy: An Historical Review From Ancient Observations to Modern Molecular Mechanisms
- Pulsed Low-Dose-Rate Radiotherapy (PLDR): A Comprehensive Review of Radiobiological Rationale and Clinical Applications in Modern Cancer Care
- Non-inferiority study of the efficacy of ranibizumab BS compared with aflibercept in patients with macular oedema due to untreated branch retinal vein occlusion: REMEDY-BRVO study - study protocol.
- Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives
BibTeX
@article{behl2026from,
title = {{From ancient remedy to modern use: cannabis and cannabinoids in cancer care in the United States}},
author = {Deepti Behl and Donald I. Abrams and Dylan M. Zylla and Stacy D. D’Andre},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1878313},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1878313},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From ancient remedy to modern use: cannabis and cannabinoids in cancer care in the United States
AU - Deepti Behl
AU - Donald I. Abrams
AU - Dylan M. Zylla
AU - Stacy D. D’Andre
PY - 2026
DA - 2026/11/05
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1878313
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1878313
AB - Cannabis, an ancient plant that has been used for millennia, is increasingly utilized by patients with cancer to alleviate symptoms related to both the disease and its treatment. This complex botanical contains multiple bioactive compounds, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the endogenous endocannabinoid system. THC has been studied the most, and synthetic cannabinoids are approved for the management of chemotherapy-induced nausea and vomiting. However, evidence supporting cannabis for other cancer-related symptoms—including chemotherapy-induced peripheral neuropathy, insomnia, appetite stimulation, and non-neuropathic pain—remains limited. CBD alone has not demonstrated consistent or meaningful clinical benefit. Although preclinical data exist, there is no clinical evidence supporting cannabis as a cancer treatment. Cannabis may interact with prescribed medications, particularly with high-dose oral formulations, and its effects on immunotherapy are under investigation. Overall, cannabis is generally well tolerated, though adverse effects can be significant. Use is discouraged in individuals under 25 years of age due to ongoing neurodevelopment, and patients with active psychiatric or cardiovascular conditions should use cannabis only under close clinical supervision.
SN - 2234-943X
ER -